About
Ben Gibson is the CEO and co-founder of Pano Therapeutics, a preclinical biotech company developing small molecules that target cellular energetics, mitochondrial Complex I biology, and age-linked disease pathways. Pano says he previously served as Managing Director of Investment Banking at Canaccord Genuity Group. Public evidence supports him as a biotech operator in the aging and therapeutics ecosystem, not as a documented investor.
Areas of interest
biotechdrug discoverymitochondrial biologymetabolic diseaseneurodevelopmental disordersFragile X syndromelongevitycorporate strategybiotech financing